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Abstract
Background—Smoking is an important cardiovascular disease risk factor, but the mechanisms 
linking smoking to blood pressure are poorly understood.
Methods and Results—Data on 141,317 participants (62,666 never, 40,669 former, 37,982 
current smokers) from 23 population-based studies were included in observational and Mendelian 
randomisation (MR) meta-analyses of the associations of smoking status and smoking heaviness 
with systolic and diastolic blood pressure (SBP, DBP), hypertension, and resting heart rate. For 
the MR analyses, a genetic variant rs16969968/rs1051730 was used as a proxy for smoking 
heaviness in current smokers. In observational analyses, current as compared with never smoking 
was associated with lower SBP, DBP, and lower hypertension risk, but with higher resting heart 
rate. In observational analyses amongst current smokers, one cigarette/day higher level of smoking 
heaviness was associated with higher (0.21 beats/minute; 95% CI 0.19; 0.24) resting heart rate, 
and slightly higher DBP (0.05 mmHg; 95% CI 0.02; 0.08) and SBP (0.08 mmHg; 95% CI 0.03; 
0.13). However, in MR analyses amongst current smokers, while each smoking increasing allele 
of rs16969968/rs1051730 was associated with higher resting heart rate (0.36 beats/minute/allele; 
95% CI 0.18; 0.54), there was no strong association with DBP, SBP, or hypertension. This would 
suggest a 7 beats/minute higher heart rate in those who smoke 20 cigarettes/day.
Conclusions—This MR meta-analysis supports a causal association of smoking heaviness with 
higher level of resting heart rate, but not with blood pressure. These findings suggest that part of 
the cardiovascular risk of smoking may operate through increasing resting heart rate.
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Introduction
Smoking is a major risk factor for cardiovascular disease (CVD), but it is not clear by which 
mechanism smoking exerts its detrimental effects on CVD. Generally, epidemiological 
studies have reported lower blood pressure levels among current smokers compared with 
nonsmokers.1-14 On the other hand, smoking cessation has been reported to be followed by a 
decrease in blood pressure.15,16 Whether the apparent association between smoking and 
lower blood pressure is causal or can be explained by confounding by lifestyle or 
socioeconomic factors related to both smoking and blood pressure remains an open question. 
Furthermore, smoking is causally associated with lower body mass index (BMI),17 and 
higher level of adiposity is strongly associated with elevated blood pressure and is also 
considered a major risk factor for hypertension.18,19 Hence, there is a strong possibility that 
the lower blood pressure observed in smokers could be explained by lower body weight 
caused by smoking. Data from observational epidemiological studies also suggest that 
smoking is associated with higher level of resting heart rate.20 However, as for blood 
pressure, various confounding factors could explain this association.
In Mendelian randomisation, causal relationships in human populations are examined by 
using genetic variants as proxies for exposures of interest. The principle of Mendelian 
randomisation relies on the basic laws of Mendelian genetics, segregation and independent 
assortment. When these principles hold at a population level, genetic variants will not be 
associated with the confounding factors that generally distort conventional observational 
studies.21 In addition, an outcome measure cannot alter the germline genotype that an 
individual is born with, so these analyses should not be affected by reverse causality. It can 
be applied in two ways – first, to establish whether an observational association is likely to 
be causal, and second, using formal instrumental variable methods, to more accurately 
estimate the magnitude of this causal effect. Here we focus on the former approach.
A genetic variant, single nucleotide polymorphism (SNP), rs16969968, in the CHRNA5-
CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster on chromosome 15 has 
demonstrated robust association with smoking heaviness within smokers.22-24 The 
rs16969968 variant is functional and leads to an amino acid change (D398N) in the nicotinic 
receptor alpha5 subunit protein.25 The minor allele of the rs16969968 SNP is associated 
with an average increase in smoking amount of one cigarette per day in smokers and is even 
more strongly associated with serum cotinine (a metabolite of nicotine) levels.24,26 
Importantly, the rs16969968 has not been robustly associated with smoking status and may 
therefore primarily be used as a marker of smoking heaviness in smokers. It is in perfect 
linkage disequilibrium with another SNP, rs1051730, and the two SNPs therefore represent 
the same genetic signal and can be used interchangeably. A large meta-analysis found that 
the minor allele of rs1051730 that increases smoking in current smokers is associated with 
lower BMI in current smokers, supporting the hypothesis that smoking is causally related to 
lower BMI.17 As expected, the effect of rs1051730 on BMI differed with smoking status; 
the negative effect was observed in current smokers but not in never smokers indicating that 
the association operate via smoking.17
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A study in 5,402 young Finnish adults examined the effects of rs1051730 on blood 
pressure.23 The smoking increasing allele of rs1051730 tended to associate with lower 
systolic and diastolic blood pressure (SBP and DBP) among current smokers, but there was 
no strong statistical evidence for these associations. Furthermore, there was no evidence of 
interaction between smoking status and rs1051730 genotype. Åsvold and colleagues looked 
at the association between rs1051730 and cardiovascular risk factors in the HUNT study.27 
In the total population including never, former, and current smokers, they found that the 
smoking increasing allele of rs1051730 was associated with lower SBP, but there was no 
association with DBP. Unexpectedly, the association between the rs1051730 and SBP was 
mainly seen among never smokers and there was no interaction between genotype and 
smoking status in relation to SBP possibly due to lack of power to detect interaction effects. 
Thus, it is not yet fully established whether smoking-related genetic variants are associated 
with blood pressure.
In this study, we investigated the associations between smoking and both blood pressure and 
resting heart rate, using both an observational and a Mendelian randomisation approach. 
First, we meta-analysed a total of 23 population-based studies participating in the 
consortium for Causal Analysis Research in Tobacco and Alcohol (CARTA).28 Second, we 
examined the possible causal effects of smoking on blood pressure and resting heart rate by 
Mendelian randomization using rs16969968/rs1051730 as unconfounded and unbiased 
proxies of smoking heaviness in current smokers.
Methods
Study Populations
The study was carried out within the CARTA consortium (http://www.bris.ac.uk/expsych/
research/brain/targ/research/collaborations/carta).28,29 We used data on individuals (aged 
≥16 years) of self-reported European ancestry from 23 studies: the 1958 British birth cohort 
(1958 BC), the Avon Longitudinal Study of Parents and Children (ALSPAC, including both 
mothers and children),30,31 the British Regional Heart Study (BRHS), the Caerphilly 
Prospective Study (CaPS), Cohorte Lausannoise (CoLaus/PsyCoLaus), the Dan-monica10 
study, the English Longitudinal Study of Ageing (ELSA), the National FINRISK Study 
(FINRISK), the Danish GEMINAKAR study (The importance of genes, familiar and 
common environment for the development of insulin resistance, abdominal adiposity and 
cardiovascular risk factors), Genetics of Overweight Young Adults (GOYA) male, 
Generation Scotland: the Scottish Family Health Study (GS:SFHS), Health2006, the 
Helsinki Birth Cohort Study (HBCS), the Nord-Trøndelag health study (HUNT), Inter99, 
MIDSPAN Family Study, the Northern Finland Birth Cohorts (NFBC1966 and NFBC1986), 
the National Health and Nutrition Examination Survey (NHANES), the MRC National 
Survey of Health and Development (NSHD), the Netherlands Twin Registry (NTR), the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), and the Whitehall II 
study. All studies received ethics approval from local research ethics committees. Further 
details of these studies are provided in supplemental material. Descriptive statistics are 
presented in Supplemental Table S1.
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Genotype
Within each study, individuals were genotyped for one of two SNPs in the CHRNA5-A3-B4 
nicotinic receptor subunit gene cluster, rs16969968 or rs1051730. These SNPs are in perfect 
linkage disequilibrium with each other in Europeans (R2 = 1.00 in HapMap 3, http://
hapmap.ncbi.nlm.nih.gov/) and therefore represent the same genetic signal. For studies with 
data available for both SNPs, the SNP that was genotyped in the largest number of 
participants was used. Details of genotyping methods within each study are provided in 
supplemental material.
Measurements of blood pressure and heart rate
Details on the methods used for measuring systolic (SBP) and diastolic (DBP) blood 
pressure (mmHg) and resting heart rate (beats per minute) in each study are provided in 
supplemental material. In cohorts where information about use of blood pressure lowering 
medication was available a constant was added to SBP (15 mmHg) and DBP (10 mmHg) in 
subjects on blood pressure lowering medication as recommended by Tobin and colleagues.32 
If this information was not available SBP and DBP were analysed as they were. Availability 
of information on blood pressure lowering medication in each study is provided in 
Supplemental Table S1. The following dichotomous outcomes were defined: 1) 
‘hypertension’ as SBP >140 mmHg or DBP >90 mmHg or taking blood pressure lowering 
medication, 2) ‘severe hypertension’ as SBP >160 mmHg or DBP >100 mmHg, or taking 
blood pressure lowering medication. Thus, participants taking blood pressure lowering 
medication were defined as having both hypertension and severe hypertension. BMI was 
calculated as weight/height2 (kg/m2). Age was calculated as years at the time of 
measurements of blood pressure and heart rate.
Smoking status
Individuals were classified as current, former, or never cigarette smokers. Where 
information on smoking frequency was available, current smokers were restricted to 
individuals smoking at least one cigarette per day. Smokers (occasional smokers) who 
reported smoking less frequently than this were excluded from analyses on smokers. Where 
information on pipe and cigar smoking was available, individuals reporting being current or 
former smokers of pipes or cigars but not cigarettes were excluded from all analyses.
For studies with adolescent populations (ALSPAC children and NFBC 86), analyses were 
restricted to current daily smokers who reported smoking at least one cigarette per day 
(current smokers) and individuals who had never tried smoking (never smokers).
Data on smoking heaviness in current smokers, measured as cigarettes smoked per day, were 
collected in most studies as a continuous variable and in a few studies as a categorical 
variable. For full details of the smoking measures collected within each study, see the 
supplemental material.
Statistical analysis
Analyses were conducted within each contributing study using Stata and R software 
following the same pre-specified analysis protocol. The analysis protocol is available on the 
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CARTA website: http://www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/
carta/
Scripts for data analyses and output for Stata and R were developed and made available to 
ensure uniform analyses and minimize errors in data extraction. Thus, analyses were 
restricted to individuals with full data on blood pressure, heart rate, smoking status and 
rs16969968/rs1051730 genotype. Within each study, genotype frequencies were tested for 
deviation from Hardy Weinberg Equilibrium using a chi-squared test.
In observational analyses, sex- and age-adjusted associations of smoking status (never, 
former, current) and smoking heaviness with continuous measures of SBP and DBP, and 
heart rate, were assessed using linear regression. For the smoking status analysis, never 
smokers were used as the reference group. The smoking heaviness analysis was restricted to 
current daily smokers, and beta estimates represent change in the outcome measure per 
additional cigarette consumed per day. Sex- and age-adjusted associations expressed as odds 
ratios (ORs) of smoking status (never, former, current) and smoking heaviness with binary 
measures of hypertension (‘hypertension’ and ‘severe hypertension’) were assessed using 
logistic regression. In additional analyses, the above models were further adjusted for BMI 
(continuous variable) to observe changes (if any) in the estimates for the effects of smoking.
Mendelian randomisation analyses of the association between rs16969968/rs1051730 and 
continuous measures of blood pressure and heart rate were assessed using linear regression 
stratified by smoking status (never, former, current) and adjusted for age, and sex. 
Mendelian randomisation analyses of the association between rs16969968/rs1051730 and 
binary measures of hypertension (‘hypertension’ and ‘severe hypertension’) were assessed 
using logistic regression stratified by smoking status (never, former, current) adjusted for 
age, and sex. An additive genetic model was assumed, so risk estimates represent the 
difference in risk of the outcome per additional copy of the minor (risk) allele. In additional 
analyses, the above models were further adjusted for BMI (continuous variable) observing 
changes in the estimates for the effects of the risk allele.
Results from individual studies were meta-analysed in Stata (version 11) using the “metan” 
command. Results from observational analyses were combined by random effects model due 
to substantial heterogeneity (I2 > 50%). Results from Mendelian randomisation analyses 
were combined in a fixed effects model and the Cochran Q statistic was used to test for 
heterogeneity between genotype and smoking status in relation to the outcome measures.
Results
Descriptive statistics
In total, data on 141,317 iindividuals were available for analysis, including 62,666 never 
smokers, 40,669 former smokers, and 37,982 current smokers. Overall, 49% of the 
combined study population was male. The median age within the contributing studies ranged 
from 16 to 75 years. Descriptive statistics for each of the study populations are found in the 
Supplemental Table S1. Minor allele frequency for rs16969968/rs1051730 ranged between 
0.29 and 0.36 (Supplemental Table S2). There was no strong evidence for deviation from 
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Hardy Weinberg Equilibrium in any of the studies (p-values all ≥ 0.1) (Supplemental Table 
S2).
Observational analysis
The meta-analysed estimates of the age- and sex-adjusted associations of smoking status 
(never, former, current smoking) with SBP, DBP, and resting heart rate are shown in Figure 
1. Study-specific estimates are shown in supplemental material. Current as compared with 
never smoking was associated with lower SBP (−2.40 mmHg; 95% CI −3.39; −1.41) and 
DBP (−1.93 mmHg; 95% CI −2.72; −1.15). Accordingly, current as compared with never 
smoking was associated with a lower risk of hypertension (OR 0.78; 95% CI: 0.70; 0.88) 
and severe hypertension (OR 0.79; 95% CI: 0.66; 0.94) (Figure 2).
The above associations were attenuated, but remained, when further adjusted for BMI 
(Supplemental Figures S1 and S2). For example, after additional adjustment for BMI, 
current as compared with never smoking was associated with a lower risk of hypertension 
(OR 0.84; 95% CI: 0.73; 0.94) and severe hypertension (OR 0.85; 95% CI: 0.72; 1.01) 
(Supplemental Figure S2).
Current as compared with never smoking was associated with 1.93 beats per minute (95% 
CI: 0.97; 2.89) higher resting heart rate (Figure 1) and this association was not attenuated by 
adjustment for BMI (Supplemental Figure S1).
The analysis of smoking heaviness (performed only in current smokers) showed that higher 
level of smoking heaviness was associated with slightly higher levels of SBP and DBP 
(Figure 3). In age- and sex-adjusted analyses, one cigarette per day higher level of smoking 
heaviness was associated with a 0.08 (95% CI: 0.03; 0.13) and 0.05 (95% CI: 0.02; 0.08) 
mmHg higher SBP and DBP, respectively. These associations attenuated after further 
adjustment for BMI (Figure S3). One cigarette per day higher level of smoking heaviness 
was associated with a 0.21 (95% CI: 0.19; 0.24) beats per minute higher level of resting 
heart rate (Figure 3), and this association was not attenuated by adjustment for BMI 
(Supplemental Figure S3).
Mendelian randomization analysis
In meta-analyses stratified by smoking status, there was no strong evidence that rs16969968/
rs1051730 was associated with either continuous measures of blood pressure (Table 1)
(Figure 4) or with binary measures of hypertension (hypertension and severe hypertension) 
(Table 1)(Supplemental Figure S4). Associations were closer to the null after adjustment for 
BMI (Supplemental Figures S5 and S6). There was no evidence that the effect of the 
CHRNA5-A3-B4 variant differed between never, former and current smokers (p-values for 
heterogeneity from Cochran Q test all >= 0.1).
In contrast, in current smokers, the smoking increasing allele of rs16969968/rs1051730 was 
associated with a 0.36 (95% CI 0.18; 0.54) beats per minute higher heart rate per allele 
(Table 1)(Figure 4). This estimate was 0.39 (95% CI 0.21; 0.57)) after additional adjustment 
for BMI (Supplemental Figure S5). In addition, there was evidence of interaction (p-value 
for heterogeneity from Cochran Q test 0.003) between smoking status and the CHRNA5-A3-
Linneberg et al. Page 6
Circ Cardiovasc Genet. Author manuscript; available in PMC 2016 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
B4 variant in age, sex and BMI-adjusted analyses lending further support to a causal effect 
of smoking on resting heart rate.
The results of observational and Mendelian Randomization analyses stratified by two 
smoking status categories (never and ever smokers) were in line with the analyses stratified 
by three smoking categories (never, former, and current smokers) (data not shown).
Additionally, sensitivity analyses were performed excluding each of the following studies: 
HUNT, ALSPAC children, and Prosper. The reasons for this were the large number of 
participants contributed by one study (HUNT), relatedness between participants (mothers 
and children in ALSPAC), and results being outliers (Prosper). These analyses yielded 
generally results similar to results based on all studies. However, when excluding the HUNT 
study, the association of the smoking increasing allele of rs16969968/rs1051730 with resting 
heart rate in current smokers attenuated and became statistically insignificant.
Finally, we investigated the association of the smoking increasing allele of rs16969968/
rs1051730 with smoking status and smoking heaviness. In current smokers, the smoking 
increasing allele of rs16969968/rs1051730 was associated with 0.9 cigarettes/day/allele 
increase in smoking heaviness (Figure 5). Our results confirmed previous findings in that the 
smoking increasing allele is not associated with smoking initiation (the allele is not 
associated with ever versus never smoking), but may be associated with smoking cessation 
(the allele is significantly associated with current versus former smoking) (Supplemental 
Figure S7).
Discussion
We performed a meta-analysis of 23 population-based studies including a total of 141,317 
individuals, using both observational and Mendelian randomisation analyses. In 
observational analyses, we found that current smoking is associated with lower blood 
pressure and lower prevalence of hypertension. However, observational and Mendelian 
randomisation analyses did not support a causal association between smoking heaviness in 
current smokers and blood pressure. In contrast, both observational and Mendelian 
randomisation analyses consistently suggested that smoking heaviness is causally related to 
increasing resting heart rate amongst smokers.
In our meta-analyses, the risk estimate for the effect of rs16969968/rs1051730 on blood 
pressure in current smokers was close to the null, with the confidence interval overlapping 
the null. Thus, the Mendelian randomisation analysis did not support a causal effect of 
smoking heaviness on blood pressure. It should be stressed that the unadjusted analysis 
captures the overall effect of smoking on blood pressure. Given evidence from previous 
Mendelian randomisation studies that smoking reduces BMI, and BMI causes higher blood 
pressure, we might have expected to see a negative association between the smoking 
increasing allele and blood pressure in current smokers, unless smoking increases blood 
pressure through other pathways. There was some indication that adjustment for BMI in our 
Mendelian randomisation analyses attenuated the estimates for the effects of the smoking 
increasing allele among current smokers even more towards the null, an observation that 
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may suggest that any potential effect of smoking on blood pressure would be mediated 
through the BMI-decreasing effect of smoking.17 It should be stressed, that if BMI acts as a 
mediator, adjustment for BMI would be inappropriate and caution should be exercised when 
interpreting the BMI adjusted results. Future studies could employ a double Mendelian 
randomization approach using genetic makers of both smoking and BMI.
Amongst current smokers, results of our Mendelian randomisation analysis supported that 
smoking heaviness is causally associated with increasing resting heart rate. These results 
thus corroborate results of our observational analysis and are furthermore in line with studies 
showing that resting heart rate tends to decrease following smoking cessation.16,33,34 The 
mechanisms by which smoking increases resting heart rate are not clear. Human 
experimental studies show that administration of nicotine increases resting heart rate and 
that this is an acute effect.35,36 Thus, when nicotine is administered intravenously the heart 
rate increasing effect peaks within the first minute after administration.36 Interestingly, it has 
been observed that reductions in hospital admissions with acute myocardial infarction 
following smoking regulation and bans in public places appear to have a surprisingly rapid 
onset.37
The clinical implications of smoking-induced higher resting heart rate are not clear. 
However, considering the well-documented detrimental effects of smoking on risk of 
cardiovascular disease and our finding that this might not involve a strong direct effect on 
blood pressure, it may be speculated that more attention should be paid to resting heart rate 
as a marker of cardiovascular health and risk prediction.38 Several studies have shown that 
resting heart rate is a predictor of cardiovascular events even after controlling for other 
cardiovascular risk factors such as blood pressure.39-44 Of potential relevance is that heart-
rate lowering drugs improve long-term survival of patients with myocardial infarction.45 
Our results roughly translated estimate that someone smoking 20 cigarettes per day could 
increase their resting heart rate by around 7 beats per min, and vice versa that someone 
stopping smoking could have this meaningful reduction in HR.
The minor allele of the rs16969968/rs1051730 is known to be associated with smoking 
heaviness by approximately 1 cigarette per day per copy of the allele in current smokers,46 
and we observed a 0.36 (95% CI 0.18; 0.54) beats per minute higher resting heart rate per 
one extra copy of the smoking increasing allele in current smokers (Figure 4). Using the 
CHRNA5-A3-B4 variant (rs16969968/rs1051730) as an instrument for tobacco exposure 
may be advantageous compared to using a self-reported measure of tobacco exposure. 
Firstly, self-reported tobacco use is likely subject to some degree of misclassification and 
reporting bias. Secondly, self-reported tobacco consumption does not take into account 
variation in smoking topography, such as the amount of a cigarette an individual smokes or 
the depth of inhalation.24 Thirdly, the CHRNA5-A3-B4 variant is an instrument for lifetime 
cumulated tobacco exposure, and this is not fully captured by cigarettes per day. In further 
support of the genetic variant being a better measure of smoking heaviness, it has been 
shown that rs16969968/rs1051730 explains more of the variance (4%) in serum cotinine, a 
biomarker of tobacco exposure, than in self-reported number of cigarettes per day (1%)24,26. 
Notably, the effect (0.21 beats per minute increase per cigarette per day) of smoking 
heaviness on resting heart rate observed in our observational analyses based on self-reported 
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smoking habits was smaller than indicated by the Mendelian randomisation analyses, a 
finding that is consistent with the idea that the rs16969968/rs1051730 SNP is a more 
accurate marker of smoking heaviness than self-reports. Of note, it has previously been 
shown that the use of instrumental variable analysis in Mendelian Randomisation studies 
estimate the magnitude of any causal effect of cigarette smoking, where measured self-
reported cigarette consumption is used as the exposure, is likely inappropriate and may lead 
to biased estimates.47
We would not expect to see an effect of rs16969968/rs1051730 on resting heart rate in never 
smokers, because the variant cannot be associated with smoking heaviness within these 
individuals without any exposure. Thus, this group can be used to test the assumption of no 
pleiotrophy (i.e. that the gene affects only one exposure) in Mendelian randomisation 
analyses. Thus, our observation that there was no clear statistical evidence for an association 
of the rs16969968/rs1051730 variant with heart rate in never smokers, and that we observed 
statistical evidence of heterogeneity of the effect of the variant between smoking categories, 
lends further support to the notion that smoking is causally related to higher resting heart 
rate.
The principle of Mendelian randomization is based of assumptions, e.g. a) the genetic 
marker is associated with the exposure, b) the genetic marker is independent of the outcome 
given the exposure and all confounders (pleitrophy, see above), and c) the genetic marker is 
independent of factors that confound the exposure-outcome relationship. It should be 
recognized that these assumptions may not all be easy to evaluate.
Stratification of Mendelian randomisation analyses may induce collider bias, if the 
instrument is predictive of the stratification variable.48 We do not think that this is a major 
concern as our instrument rs16969968/rs1051730 is primarily a genetic variant for smoking 
heaviness within smokers and there is no clear evidence that it is associated with smoking 
initiation (i.e. being an ever versus a never smoker). It does show some evidence for an 
association with smoking cessation,49 but analyses performed in ever smokers yielded 
results similar to analyses performed in current smokers. The rs16969968/rs1051730 variant 
has been used in a similar way (i.e. stratified on smoking status) in a number of other 
Mendelian Randomisation studies to demonstrate the expected causal associations of 
smoking with increased all-cause mortality,50 decreased lung function,51 and body mass 
index. The fact that stratification by smoking status has been used to show that smoking is, 
as expected, causally related these phenotypes, supports our view that this approach is 
appropriate.
Conclusions
This large Mendelian randomization meta-analysis suggests that smoking is causally related 
to higher level of resting heart rate, but not to alterations in blood pressure and risk of 
hypertension. These findings are consistent with the hypothesis that smoking exerts its 
detrimental effects on cardiovascular disease at least partly via increasing resting heart rate.
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Clinical Perspective
Smoking is a major risk factor for cardiovascular disease, but it is not clear by which 
mechanism smoking exerts its detrimental effects on cardiovascular disease. Previous 
observational epidemiological studies show that smokers as compared to non-smokers 
have lower blood pressure and risk of hypertension. However, these studies may have 
been hampered by confounding and biases. Mendelian randomization is an approach 
where genetic markers of exposures are used for testing causal associations. We 
performed a meta-analysis of 23 population-based studies including a total of 141,317 
individuals, using both observational and Mendelian randomization analyses. Our results 
suggested that smoking is causally related to higher level of resting heart rate, but not to 
significant alterations in blood pressure and risk of hypertension. These findings are 
consistent with the hypothesis that smoking exerts its detrimental effects on 
cardiovascular disease at least partly via increasing resting heart rate. Our results roughly 
translated estimate that someone smoking 20 cigarettes per day could increase their 
resting heart rate by around 7 beats per min, and vice versa that someone stopping 
smoking could have this meaningful reduction in heart rate. Considering the well-
documented detrimental effects of smoking on risk of cardiovascular disease and our 
finding that this might not involve a strong direct effect on blood pressure, it may be 
speculated that more attention should be paid to resting heart rate as a marker of 
cardiovascular health and risk prediction.
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Figure 1. 
Association of smoking status with systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), and resting heart rate (RHR). Former and current smoking status are 
compared to never smoking status; the difference was estimated by linear regression 
adjusted for sex and age.
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Figure 2. 
Association of smoking status with hypertension and severe hypertension. Former and 
current smoking status are compared to never smoking status; the difference was estimated 
by logistic regression adjusted for sex and age. OR, Odds ratio.
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Figure 3. 
Association of smoking heaviness in current smokers with systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) and resting heart rate (RHR). The difference per one 
cigarette per day increase in smoking heaviness was estimated by linear regression adjusted 
for sex and age.
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Figure 4. 
Mendelian randomisation analysis of the association of the smoking increasing allele (minor 
allele) of rs1051730/rs16969968 with systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) and resting heart rate (RHR). Analyses were stratified by smoking status 
(current, former, and never smoking). The difference per one allele was estimated by linear 
regression adjusted for sex and age. Overall test for heterogeneity by smoking status: SBP: 
P=0.656; DBP: P=0.138; RHR: P=0.015;
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Figure 5. 
Mendelian randomisation analysis of the association of the smoking increasing allele (minor 
allele) of rs1051730/rs16969968 with smoking heaviness in current smokers. The difference 
(increase in smoking quantity) per one allele was estimated by linear regression adjusted for 
sex and age.
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Table 1
Mendelian randomization meta-analysis: results of meta-analysed estimates of the association of the smoking 
increasing allele of rs16969968/rs1051730 with continuous measures of blood pressure, binary measures of 
hypertension (hypertension and severe hypertension), and the continuous measure of resting heart rate. Results 
were stratified by smoking status.
Never smokers Former smokers Current smokers
Systolic blood pressure
beta-coefficient* (95% CI); mmHg/allele
−0.07 (−0.28; 0.13)
P = 0.479
−0.03 (−0.31; 0.25)
P = 0.824
−0.20 (−0.46; 0.06)
P = 0.136
Diastolic blood pressure
beta-coefficient* (95% CI); mmHg/allele
0.01 (−0.12; 0.14)
P = 0.879
0.08 (−0.09; 0.26)
P = 0.331
−0.15 (−0.32; 0.02)
P = 0.079
Hypertension
Odds ratio* (95% CI) per allele
1.00 (0.97; 1.03)
P = 0.923
1.00 (0.96; 1.03)
P = 0.811
0.98 (0.95; 1.02)
P = 0.277
Severe hypertension
Odds ratio* (95% CI) per allele
1.02 (0.98; 1.05)
P = 0.362
1.01 (0.97; 1.05)
P = 0.543
0.96 (0.92; 1.00)
P = 0.061
Resting heart rate
beta-coefficient* (95% CI); beats/minute/allele
0.03 (−0.11; 0.17)
P = 0.686
0.15 (−0.03; 0.33)
P = 0.109
0.36 (0.18; 0.54)
P < 0.001 †
*
associations have been adjusted for sex and age by linear (continuous outcomes) or logistic (binary outcomes) regression
†
Bonferroni-adjusted (15 tests) P-value was 0.001
CI confidence interval
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